Outlook Therapeutics, Inc. (OTLK) News
Track canonical SquawkNews coverage tagged to OTLK, Outlook Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
OTLK Falls After Hours
OTLK is falling after hours with no magnitude or catalyst supplied
EQUITY | Aug 12, 2026, 08:01 PM UTC
L
Outlook Therapeutics Director Buys 95,398 Shares
Director buys 95,398 shares at $1.048
FX | Jul 29, 2026, 07:20 PM UTC
L
Outlook Therapeutics price target raised by $1.10 at H.C. Wainwright, here's why
Outlook Therapeutics price target raised by $1.10 at H.C. Wainwright, here's why
EQUITY | Jul 27, 2026, 04:08 PM UTC
L
OTLK upgraded from Neutral to Buy W/ $4 PT @ BTIG
OTLK upgraded from Neutral to Buy W/ $4 PT @ BTIG
EQUITY | Jul 27, 2026, 12:47 PM UTC
L
OTLK Upgrade from Neutral to Buy W/$4.00 PT at BTIG
OTLK Upgrade from Neutral to Buy W/$4.00 PT at BTIG
EQUITY | Jul 27, 2026, 12:07 PM UTC
L
OTLK resumes trading after halt, now down -9%
OTLK resumes trading after halt, now down -9%
EQUITY | Jul 24, 2026, 07:06 PM UTC
L
REGN seeing little to no movement post OTLK jumping 24% on FDA approval of Lytenava for wet AMD thus far
REGN seeing little to no movement post OTLK jumping 24% on FDA approval of Lytenava for wet AMD thus far
REGULATION | Jul 24, 2026, 06:52 PM UTC
L
OTLK outlook Therapeutics - lytenava expected to be available to U.S. patients before year-end
OTLK outlook Therapeutics - lytenava expected to be available to U.S. patients before year-end
EQUITY | Jul 24, 2026, 06:40 PM UTC
L
OTLK outlook Therapeutics announces lytenava™ FDA approval as the first and only FDA-approved ophthalmic bevacizumab for the treatment of we
OTLK outlook Therapeutics announces lytenava™ FDA approval as the first and only FDA-approved ophthalmic bevacizumab for the treatment of wet amd Outlook Therapeutics - lytenava anticipated to have 12 years of market exc
REGULATION | Jul 24, 2026, 06:40 PM UTC
L
ELVT SNY OTSKY MNKD OTLK VTRS Here are the key confirmed or reported upcoming PDUFA (Prescription Drug User Fee Act) target action dates for
ELVT SNY OTSKY MNKD OTLK VTRS Here are the key confirmed or reported upcoming PDUFA (Prescription Drug User Fee Act) target action dates for remainder of month: --ELVT expected around 7/23 – Drug rivoceranib + camrelizum
EQUITY | Jul 20, 2026, 05:31 PM UTC